GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

31

HCC with PVTT: Liver Cancer | April 2026

Introduction Hepatocellular carcinoma with portal vein tumor thrombus represents one of the most aggressive forms of liver cancer, associated with poor prognosis and limited survival. Standard treatment relies...

32

Nutrition in MASLD: Frontline Gastroenterology | 2026

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease worldwide and closely parallels the epidemics of obesity and type 2 diabetes....

33

Adjuvant Immunotherapy in HCC: JGH | March 2026

Introduction Hepatocellular carcinoma remains a major global cancer burden, with high recurrence rates even after curative therapies such as resection or ablation. Historically, effective adjuvant treatments have been...

34

Bridging the Gap in HCC Care: CGH | April 2026

Introduction Hepatocellular carcinoma (HCC) outcomes are critically dependent on stage at diagnosis, with early-stage disease offering opportunities for curative therapies such as resection, ablation, or transplantation. Despite advances...

35

Fibrolamellar Carcinoma: Hepatology | March 2026

Introduction Fibrolamellar carcinoma (FLC) is a rare and biologically distinct primary liver cancer that predominantly affects adolescents and young adults without cirrhosis or other chronic liver disease. Unlike...

36

Microbial Metabolism follwoing TACE: Journal of Hepatology | April 2026

Introduction Transarterial chemoembolization (TACE) remains one of the most important treatments for unresectable hepatocellular carcinoma, but its clinical benefit is often limited by post-procedural liver injury. Traditionally, this...

37

BCLC Classification and AI-Based Image Quantification in HCC: Journal of Hepatology | March 2026

Introduction The Barcelona Clinic Liver Cancer (BCLC) classification has remained the cornerstone for staging, prognosis, and treatment allocation in hepatocellular carcinoma for more than two decades. Its strength...

38

Hypothermic Oxygenated Machine Perfusion Reduces HCC Recurrence After LT: JHEP March 2026

Recurrence of hepatocellular carcinoma (HCC) after liver transplantation occurs in 15–20% of patients and remains a major determinant of post-transplant survival. This international matched cohort study evaluated whether...

39

Biomarkers + USG and HCC Detection: Gastroenterology | March 2026

Introduction: The Biomarkers Used for HCC Surveillance Ultrasound (US) is the backbone of hepatocellular carcinoma (HCC) surveillance, but its sensitivity for early-stage HCC is imperfect. Blood-based biomarkers are...

40

AFP Thresholds for HCC Screening: Gastroenterology | March 2026

Introduction Alpha-fetoprotein (AFP) remains the most widely used biomarker in hepatocellular carcinoma (HCC) surveillance. Although AFP alone is insufficient for screening, its combination with ultrasound improves early HCC...

Previous
1234567
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer